Digital Transformation and Sustainability Evangelist Vijay Sethi Joins the Advisory Board of Cyble
11.5.2021 11:42:00 EEST | Business Wire | Press release
Cyble, an AI-powered, Y Combinator-backed, cyber intelligence company that empowers organizations with darkweb/cybercrime monitoring and mitigation services, today announced the addition of eminent technology and sustainability evangelist Vijay Sethi to its Advisory Board. Vijay has rich experience in advising and mentoring corporates and startups in various facets of management, digital transformation, and sustainability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005525/en/
Digital Transformation and Sustainability Evangelist Vijay Sethi Joins the Advisory Board of Cyble (Photo: Business Wire)
“A key member of our Advisory Board, Vijay’s insights will help steer our strategic development initiatives. His appointment is in line with Cyble’s commitment to achieving our goals by ensuring sustained growth, maintaining operational excellence, establishing a culture of innovation, and raising the standards for corporate governance. As Cyble continues to deliver advanced threat intelligence to its end-clients, I look forward to working with Vijay as Cyble continues to grow and span across uncharted territories,” says Manish Chachada, COO and Co-founder of Cyble.
An industry veteran with over 30 years of experience, Vijay Sethi has served as the CIO, CHRO, and Head CSR at Hero MotoCorp. Prior to that, he worked with Ranbaxy and Tata Consultancy Services. A huge proponent of digital technologies like the Cloud, Mobility, Artificial Intelligence, RPA, AR, VR, and cybersecurity and risk management, he has experience in digital transformation roadmap and project development ventures, large-scale IT projects, community development programs, and talent development and employee engagement campaigns.
Commenting on joining forces with Cyble, Vijay says, “I strongly endorse the growing need to make the digital world safer and help share cybersecurity insights and threat intelligence with consumers. The team at Cyble, their technological offerings, and the company’s commitment to keeping customers and users safe are impressive. I’m very pleased to be joining Cyble as an Advisor and look forward to working with its talented and dynamic teams.”
Rated among India’s Best IT leaders, over the years, Vijay has won several prestigious recognitions, including CIO of the year many times, CIO Hall of Fame, Super League CIO, Champion CIO, Global CIO, Global CIO Hall of fame, Digital Icon of India, India’s Best IT manager, India’s Most Innovative CSR Leader, and many others. He also serves as the Chairman of SAP India User Group (INDUS). Earlier, he also served as the Chairman of the IT Committee of Society of the Indian Automobile Manufacturers (SIAM) and the Chairman of CSR Committee of SIAM. Over the years, Vijay has also been a member of various Committees of CII and FICCI.
Beenu Arora, CEO and Founder of Cyble, says, “I am delighted to welcome Vijay into the board. He truly needs no introduction in the cybersecurity fraternity, and his problem-solving skills and passion for building efficient solutions make him best suited to take Cyble to the next level. His appointment has been a significant step in our effort to nurture our world-class business leadership team. Vijay’s actionable counsel will prove beneficial in shaping Cyble’s strategic business decisions.”
About Cyble:
Cyble is a global threat intelligence SaaS provider that helps enterprises protect themselves from cybercrimes and exposure in the Darkweb. Its prime focus is to provide organizations with real-time visibility to their digital risk footprint. Backed by Y Combinator as part of the 2021 winter cohort, Cyble has also been recognized by Forbes as one of the top 20 Best Cybersecurity Start-ups To Watch In 2020. Headquartered in Alpharetta, Georgia, and with offices in Australia, Singapore, and India, Cyble has a global presence. To learn more about Cyble, visit www.cyble.io.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005525/en/
Contact information
Medha Roy Chowdhury
EMAIL:
Enquiries@Cyble.io
MOBILE: +1 678 379 3241
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
Cranium AI and ISTARI Forge Global Alliance to Drive Enterprise AI Security and Governance21.5.2026 13:00:00 EEST | Press release
Cranium AI, the leading end-to-end AI Security and Governance platform, and ISTARI, a leading cyber resilience advisory firm, today announced a strategic partnership to provide global organizations with an end-to-end AI security & governance solution. As organizations accelerate AI adoption, they face a critical challenge: implementing actionable, operational AI governance while keeping pace with the speed of the AI landscape. This collaboration bridges that gap by merging Cranium’s cutting-edge AI security and governance platform with ISTARI’s deep advisory expertise in cyber risk and operating model design. Together, the firms provide a powerful, end-to-end solution for enterprises navigating the complexities of AI transformation. A Unified Vision for Sustainable AI Governance The partnership is built on a shared mission to move organizations beyond fragmented AI initiatives toward fully operationalized, secure, and governed programs. By combining Cranium’s platform automation with I
Cognite and ABB Collaborate to Integrate Agentic AI into Industrial Applications to Deliver Faster Workflows21.5.2026 13:00:00 EEST | Press release
Cognite, the leader in Industrial AI, today announced a collaboration with ABB to assess how advanced industrial AI and data capabilities can be integrated to solve key use cases in the energy sector. By adding an agentic layer to established industrial applications, including ABB Ability™ SafetyInsight™ and ABB Ability™ AlarmInsight™, using the Cognite Industrial AI and Data platform, the collaboration aims to enable "agent-to-agent" orchestration. Leading energy producer Aker BP has signed on as the first customer to implement this new generation of intelligent offerings as part of its strategy to further increase its current production efficiency of 96% and achieve a production growth target of 525,000 barrels of oil equivalent per day by 2028. Transforming Data into Actionable Business Value By breaking down traditional data silos and shifting to outcome-based software orchestration, the collaboration aims to deliver significant business value to ABB and Cognite customers, includin
BeOne Medicines Sets the Pace in Oncology at ASCO and EHA 2026 with 60+ Abstracts21.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that more than 60 abstracts across hematologic malignancies and solid tumors have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (May 29–June 2, Chicago) and the 2026 European Hematology Association (EHA) Congress (June 11–14, Stockholm). Continuing to raise the bar in CLL At ASCO and EHA 2026, BeOne will showcase its hematology leadership with data spanning foundational therapies and next-generation innovation across CLL, mantle cell lymphoma and other B-cell malignancies. The data emphasize impressive long-term outcomes, durability across patient populations, and a disciplined approach to advancing future regimens. Collectively, these data underscore BeOne’s strategy to lead in hematology science and patient impact by setting the standard today – while helping to shape the future of CLL. Amit Agarwal, M.D., Ph.D., Chief Medic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
